COH – Citi rates the stock as Neutral

By Broker News | More Articles by Broker News

Citi analysts express their concern that Cochlear might be legally ordered to pay a considerable amount in its patent dispute with the Al Mann Foundation (AMF) while trading on a lofty PE multiple.

The analysts note the company has taken a provision of US$20m but this could prove insufficient with Citi estimating the final damages award can be as high as US$500m. Neutral. Target $127.50.

Sector: Health Care Equipment & Services.

Target price is $127.50.Current Price is $135.26. Difference: ($7.76) – (brackets indicate current price is over target). If COH meets the Citi target it will return approximately -6% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →